NHS England has published its Combined Performance Summary, which provides data on key performance measures for January and February of this year. Here Jessica Morris of the Nuffield Trust shows some of these statistics and how they compare with previous years.
Office for National Statistics | January 2019 | Cancer survival in England: national estimates for patients followed up to 2017
The latest release of Cancer survival in England: national estimates for patients followed up to 2017 has been published by the Office for National Statistics.
For the first time we have been able to produce robust 1-year and 5-year net cancer survival estimates by stage at diagnosis based on five years’ worth of cancer diagnoses (2012 to 2016), making them comparable with the adult cancer survival estimates.
Adults diagnosed at stage 1 with either melanoma of the skin, prostate or breast (women only) cancer have the same chance of surviving 1-year after diagnosis as an individual in the general population.
Melanoma of the skin had the highest net-survival estimate for 1-year survival in both men (97.4%) and women (98.6%) and for 5-year survival in both men (89.2%) and women (93.9%).
Pancreatic cancer had the lowest net-survival estimate for 1-year survival in men (23.7%) and women (25.3%) and for 5-year survival in both men (6.4%) and women (7.5%).
Predicted 10-year survival was also highest for melanoma of the skin for both men and women at 85.0% and 90.9% respectively, and lowest for lung cancer for both men and women at 7.0% and 10.6% respectively.
Sarah Caul, Head of Cancer Analysis, said:
“In general, we have seen an increase in people’s chances of survival across different types of cancer since our estimates for 2006 to 2010. Melanoma of the skin, prostate and breast cancer have continued to have the highest chances of survival across all age-standardised estimates compared to other cancer types. The higher survival figures could partly be explained by a high percentage of prostate and breast cancer patients being diagnosed at an earlier stage”
Office of Health Economics | July 2018 | Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
The Office of Health Economics has undertaken a literature review which examines whether there is evidence to support the assumption that the quality of life (QoL) of long-term cancer survivors (LTCS) can be similar to that of age-/sex-matched population samples. The review included 20 papers which represented 23 studies covering a range of cancers, with the LTCS in the studies were more likely to have experienced early-stage cancer relative to late-stage cancer (Source: Office of Health Economics).
Little evidence for any direct impact of national cancer policies on short-term survival in England and no evidence for a reduction in socioeconomic inequalities in cancer survival. Findings emphasise that socioeconomic inequalities in survival remain a major public health problem. | London School of Hygiene & Tropical Medicine | British Medical Journal
New research from the London School of Hygiene and Tropical Medicine found that despite overall improvements in cancer survival, the gap in survival between the most affluent and most deprived groups of patients remains unchanged for most cancers.
Survival trends were examined for 21 cancers in men and 20 cancers in women.
For each cancer, the chances of survival at one year after diagnosis were estimated separately for men and women in five levels of socio-economic deprivation, from the most affluent to the most deprived, and in each of the three calendar periods.
Researchers focused on one-year survival because most of the inequalities in cancer survival in England arise shortly after diagnosis. The survival estimates were corrected for the risk of dying from other causes of death. Estimates were also adjusted for differences in the age profile of cancer patients between men and women, and over time.
The “deprivation gap” in survival between the most affluent and most deprived groups of patients remained unchanged for most cancers. There was a clear and persistent pattern of lower survival among more deprived patients. It narrowed slightly for some cancers, where one-year survival was already more than 65% in 1996, such as cervical cancer and skin melanoma in men. By contrast, the deprivation gap in survival widened between the late 1990s and 2013 for brain tumours in men and lung cancer in women.
Bowel cancer is the UK’s second biggest cancer killer with 16,000 people dying from the disease, and the fourth most common cancer with over 41,200 people diagnosed each year. The key to reducing the numbers of people dying from this condition is early diagnosis. This report examines ways and methods of increasing earlier detection methods which could transform survival rates and ultimately benefit thousands of people in the future.
Health at a Glance 2017: OECD Indicators | Organisation for Economic Cooperation and Development | OnMedica
A report from the Organisation for Economic Cooperation and Development (OECD) has found that the UK has the sixth highest rate of adult obesity. The report looks at health indicators across its 100 member countries.
It shows that almost 27% of the adult population of the UK is obese, compared with the OECD average of 19.4%. The UK has a smoking prevalence of 16.1%, which is below the OECD average of 18.4%.
However average alcohol consumption per UK adult is higher than the OECD average, with consumption averaging at 9.5 litres per adult.
The report highlights cancer by way of an example of both the good progress made and continuing challenges. Cancer survival has improved over time, due in part to high screening rates. Breast and rectal cancer survival rates are now slightly higher than the OECD average, with, respectively, 85.6% and 62.5% of people diagnosed living for at least a further five years, versus 85% and 61% in the OECD as a whole. Both rose at a faster pace than average over the course of ten years. But bowel cancer survival is still below the OECD average (60% compared to 62.8%), and overall cancer mortality rates remain relatively high (222 deaths per 100 000 people, compared with an OECD average of 204).
The rate of people dying from bowel cancer in the UK has plummeted by more than 30 per cent in the last 20 years | Cancer Research UK
Bowel cancer was responsible for 38 deaths per 100,000 people in 1995, falling to 26 deaths per 100,000 people by 2015. The drop in rates, taking into account changing population figures, equates to a decrease in bowel cancer deaths from 17,600 in 1995 to 15,800 in 2015.
Experts believe better treatment lies behind the dramatic drop in deaths. Improved public awareness among both patients and doctors, the bowel screening programme, may also be playing a part.